Results 111 to 120 of about 11,617 (148)

Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations. [PDF]

Biomedicines
Dascalu AM, Grigorescu CC, Ergin E, Alexandrescu C, Dumitrescu D, Nedea MI, Cristea BM, Serban D, Tribus LC, Badescu TM.   +9 more
europepmc   +1 more source

Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration. [PDF]

Jpn J Ophthalmol
Kindo H, Hosokawa MM, Ouchi C, Matoba R, Morita T, Hayashi J, Morizane Y.   +6 more
europepmc   +1 more source

Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report. [PDF]

Am J Case Rep
Sano H, Yanai R, Mitamura Y.
europepmc   +1 more source

Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. [PDF]

J Comp Eff Res
Shi F, Tan S, Shu Y, Liu T, Xia Y, Buehrer C, Han S.   +6 more
europepmc   +1 more source

Management of diabetic macular edema: from anti-VEGF to emerging therapies. [PDF]

Front Med (Lausanne)
Ji M, Wei W, Gong H, Zhang G.
europepmc   +1 more source

Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration. [PDF]

PLoS One
Iby J, Coulibaly L, Hollaus M, Yeghiazaryan L, Schmidt-Erfurth U, Bühl W, Sacu S.   +6 more
europepmc   +1 more source

Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment. [PDF]

PLoS One
Tomemori R, Mori H, Tanaka M, Kiriishi T, Omi M, Hattori Y, Oba S, Ohnaka M, Imai H.   +8 more
europepmc   +1 more source

Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis. [PDF]

Ophthalmol Ther
Zhang R, Tunon-Robinson I, Nguyen AK.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aflibercept

Reactions Weekly, 2022
  +6 more sources